ImmuCell Corporation Common Stock (NASDAQ: ICCC) last traded at $10.06, down 0.30% on the session. The quote above updates while this page is open; the figures below are drawn from ImmuCell Corporation Common Stock’s own filings and are restated only when a new one is published.
ImmuCell Corporation Common Stock trades on NASDAQ under the ticker ICCC. Its market capitalisation is $91.37 million.
Valuation measures for ImmuCell Corporation Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $91.37M |
|---|---|
| Enterprise value | $97.76M |
| P/E ratio | 143.71 |
| Price / sales | 2.98 |
| Price / book | 2.91 |
| Beta | 0.37 |
Trailing-twelve-month figures tagged in ImmuCell Corporation Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $30.68M |
|---|---|
| Net income (TTM) | $787.4K |
| EPS (TTM) | $0.0700 |
| Gross margin | 40.32% |
| Operating margin | 12.60% |
| Return on equity | 2.51% |
| Cash | $8.86M |
Range and volume for ICCC over the past 52 weeks.
| 52-week high | $12.10 |
|---|---|
| 52-week low | $4.52 |
| Volume | 10.9K |
| Average volume | 30.8K |
| Previous close | $10.09 |
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.